{"publication_id":"529fbc6c-66ad-49b5-910a-f2b076cb190c","screening":{"identified":19,"screened":19,"excluded":0,"included":19,"included_or_retained":19,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"19 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["The conclusion is that NAD+ metabolism effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","Signal-accounting note: biomarker-positive source-level findings are separated from clinical-endpoint mixed/null rows; biomarker elevation is not counted as clinical efficacy unless the mapped outcome class and endpoint support it.","Tension-accounting note: disagreement counts are claim-level. Substantive tension still remains between biomarker-elevating studies and mixed/null clinical-endpoint studies across cognition, menopause, acute-care, so these contrasts are treated as unresolved evidence gaps.","Ryu 2022: Nicotinamide riboside and caffeine partially restore diminished NAD availability but not altered energy metabolism in Alzheimer's disease: outcome=Contextual Adjacent Evidence; directness=indirect; tier=B2."]}